Sandra L Kletzel1, Juan Manuel Hernandez2, Elizabeth F Miskiel2, Trudy Mallinson3, Theresa Louise-Bender Pape4. 1. The Department of Veterans Affairs (VA), Center for Innovation in Complex Chronic Healthcare & Research Service, Edward Hines Jr. VA Hospital, PO 5000 S. 5th Avenue, Bldg. 1, (M/C 151H), Hines, IL 60141, USA. Electronic address: Sandra.kletzel@va.gov. 2. The Department of Veterans Affairs (VA), Center for Innovation in Complex Chronic Healthcare & Research Service, Edward Hines Jr. VA Hospital, PO 5000 S. 5th Avenue, Bldg. 1, (M/C 151H), Hines, IL 60141, USA; Department of Clinical Psychology Psy.D. Program, Doctoral Emphasis in Military Clinical Psychology, Adler University, Chicago, IL 60602, USA. 3. Department of Clinical Research and Leadership, The George Washington University, Washington, DC 20037, USA. 4. The Department of Veterans Affairs (VA), Center for Innovation in Complex Chronic Healthcare & Research Service, Edward Hines Jr. VA Hospital, PO 5000 S. 5th Avenue, Bldg. 1, (M/C 151H), Hines, IL 60141, USA; Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Abstract
INTRODUCTION: Mild cognitive impairment is common in Parkinson's disease, even in the early stages, and can be a risk for developing dementia. To properly track development and progression of cognitive impairment, reliable measurement tools are necessary. The Montreal Cognitive Assessment is currently used as a global cognitive screening tool and has been recommended as an abbreviated diagnostic tool to measure mild cognitive impairment in the context of global cognitive function. However psychometric properties of the Montreal Cognitive Assessment in PD have not been assessed in this context. METHODS: Data were obtained from the Parkinson's Progression Markers Initiative (n = 395). We examine psychometric properties of the Montreal Cognitive Assessment among newly diagnosed Parkinson's disease patients using Rasch analysis. RESULTS: Only one item misfit the measurement model and principle component analysis indicated the Montreal Cognitive Assessment was unidimensional. Distribution of items calibrations formed a logical hierarchy from least to most challenging. Test items were markedly off-target (i.e., too easy) for this sample; this was also reflected in low person separation reliability. While 37% of participants performed all items correctly indicating a large ceiling effect, 22% of participants obtained a raw score in the range of 21-25 indicating mild cognitive impairment. No meaningful differential item functioning was detected. CONCLUSION: Results suggest that in the context of early stage Parkinson's disease, the Montreal Cognitive Assessment is a unidimensional measure of global cognitive function. Implications for the use of the Montreal Cognitive Assessment in early stage Parkinson's disease and potential improvements to the assessment are discussed. Published by Elsevier Ltd.
INTRODUCTION: Mild cognitive impairment is common in Parkinson's disease, even in the early stages, and can be a risk for developing dementia. To properly track development and progression of cognitive impairment, reliable measurement tools are necessary. The Montreal Cognitive Assessment is currently used as a global cognitive screening tool and has been recommended as an abbreviated diagnostic tool to measure mild cognitive impairment in the context of global cognitive function. However psychometric properties of the Montreal Cognitive Assessment in PD have not been assessed in this context. METHODS: Data were obtained from the Parkinson's Progression Markers Initiative (n = 395). We examine psychometric properties of the Montreal Cognitive Assessment among newly diagnosed Parkinson's diseasepatients using Rasch analysis. RESULTS: Only one item misfit the measurement model and principle component analysis indicated the Montreal Cognitive Assessment was unidimensional. Distribution of items calibrations formed a logical hierarchy from least to most challenging. Test items were markedly off-target (i.e., too easy) for this sample; this was also reflected in low person separation reliability. While 37% of participants performed all items correctly indicating a large ceiling effect, 22% of participants obtained a raw score in the range of 21-25 indicating mild cognitive impairment. No meaningful differential item functioning was detected. CONCLUSION: Results suggest that in the context of early stage Parkinson's disease, the Montreal Cognitive Assessment is a unidimensional measure of global cognitive function. Implications for the use of the Montreal Cognitive Assessment in early stage Parkinson's disease and potential improvements to the assessment are discussed. Published by Elsevier Ltd.
Entities:
Keywords:
Cognition; Montreal Cognitive Assessment; Parkinson's disease; Psychometrics; Rasch analysis
Authors: Jason K Longhurst; John V Rider; Jeffrey L Cummings; Samantha E John; Brach Poston; Elissa C Held Bradford; Merrill R Landers Journal: Neurorehabil Neural Repair Date: 2022-04-06 Impact factor: 4.895
Authors: Rafael B Stern; Matheus Silva d'Alencar; Yanina L Uscapi; Marco D Gubitoso; Antonio C Roque; André F Helene; Maria Elisa Pimentel Piemonte Journal: Front Aging Neurosci Date: 2020-03-04 Impact factor: 5.750